Clinical Trials Logo

SARS-CoV Infection clinical trials

View clinical trials related to SARS-CoV Infection.

Filter by:

NCT ID: NCT04514874 Completed - Covid19 Clinical Trials

Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020

Covaé
Start date: September 1, 2020
Phase:
Study type: Observational

The aeronautical community was also affected and greatly impacted economically and socially by the Covid-19 pandemic. Away from the acute phase, the epidemiological impact and the consequences of this disease within the French aviation flight crew population must be assessed. This study is aimed at providing original epidemiological data among civil and military aircrew, prior to possible prevention strategies or countermeasures to optimize risk management in terms of aviation safety and to promote, if necessary, future targeted studies.

NCT ID: NCT04514016 Completed - Covid19 Clinical Trials

Cross Sectional CFAR HIV/COVID-19 Study

Start date: August 12, 2020
Phase:
Study type: Observational

The main purpose of this research study is to learn the rate of SARS COV-2 on HIV infected children, adolescents, and youth receiving their primary HIV care at the University of Miami Miller School of Medicine.

NCT ID: NCT04510194 Completed - Covid19 Clinical Trials

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

Start date: January 1, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to understand whether: 1. Metformin vs fluvoxamine vs ivermectin vs metformin+fluvoxamine vs metformin+ivermectin is superior to placebo in non-hospitalized adults with SARS-CoV-2 disease for preventing Covid-19 disease progression. 2. To understand if the active treatment arms are superior to placebo in improving viral load, serologic markers associated with Covid-19, and gut microbiome in non-hospitalized adults with SARS-CoV-2 infection. 3. To understand if any of the active treatment arms prevent long-covid syndrome, PASC (post-acute sequelae of SARS-CoV-2 infection).

NCT ID: NCT04510012 Completed - Covid-19 Clinical Trials

Characterizing the Immune Response and Neuronal Damage in COVID-19

Start date: March 5, 2020
Phase:
Study type: Observational

The Investigators plan to study the innate and adaptive immune response, the inflammatory response, and associated complications such as complement activation and neurological damage in SARS-Cov-2 infected individuals. Patients with mild, moderate and severe COVID-19 disease will be enrolled.

NCT ID: NCT04506515 Completed - Covid19 Clinical Trials

Psychological Impact of COVID-19 Pandemic in Healthcare Workers

PSIMCOV
Start date: April 9, 2020
Phase:
Study type: Observational

Background. The current coronavirus disease (COVID-19) has a great impact worldwide. Healthcare workers play an essential role and are one of the most exposed groups.Information about the psychosocial impact on healthcare workers is limited. Methods. 3109 healthcare workers completed a national, internet-based, cross-sectional 45-item survey between 9 and 19 April 2020. The objective is to assess the psychological impact of the COVID-19 pandemic in Spanish healthcare workers. A Psychological Stress and Adaptation at work Score (PSAS) was defined combining four modified versions of validated psychological assessment tests (A) Healthcare Stressful Test, (B) Coping Strategies Inventory,(C) Font-Roja Questionnaire and (D) Trait Meta-Mood Scale.

NCT ID: NCT04494386 Completed - Covid19 Clinical Trials

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

ULSC
Start date: December 23, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

ULSC-CV-01 is a clinical trial that comprises both Phase 1 and Phase 2a, which will be conducted sequentially. This trial will evaluate the safety and potential efficacy of allogeneic Umbilical Cord Lining Stem Cells (ULSC), which are a type of umbilical cord tissue derived mesenchymal stem cells (MSC), with intravenous (IV) administration in hospitalized patients with acute respiratory distress syndrome (ARDS) due to COVID-19.

NCT ID: NCT04490850 Completed - Covid19 Clinical Trials

COVID-19 Seroprevalence Study in French Guiana

EPI-COVID-POP
Start date: July 15, 2020
Phase: N/A
Study type: Interventional

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

NCT ID: NCT04490473 Recruiting - Anxiety Clinical Trials

Turkish of the SARS-CoV-2 Anxiety Scale

Start date: July 24, 2020
Phase: N/A
Study type: Interventional

The coronavirus outbreak has adversely affected individuals in the community, as in the rest of the world. However, in order to carry out this epidemic period in a healthy and conscious manner, determining the anxiety levels of individuals in the society and supporting them psychologically is of great importance. In order to achieve this, healthcare professionals working clinically or academically have important duties. This study was planned to test its validity and reliability in order to adapt the Coronavirus Anxiety Scale to Turkish.

NCT ID: NCT04490200 Completed - Covid19 Clinical Trials

Effectiveness of a Novel Respirator With Chitosan Nanoparticles

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

The use of nanomaterials in semi-facial respirators could decrease the permeability of particles and promote a biocidal effect compared to conventional respirators (N95) and, therefore, to enhance the filtering power, aiming to mitigate harmful effects of bacteria and viruses. Chitosan is a natural cationic polymer derived from chitin, with characteristics such as being biodegradable, biocompatible, non-toxic, and presenting antimicrobial activity. This polymer has virucidal activity in several types of viruses, including other coronaviruses, given the attractive factor of its cationic charge for negative charges. The effectiveness of a novel individual protection semi-facial respirator (called VESTA) will be investigated, compared to a conventional N95 respirator. The respirators will be tested in healthcare professionals working in hospital environments and the effectiveness will be attributed to the lower incidence rate of infection by the SARS-CoV-2, and to the ability to filter these viruses after use by healthcare professionals exposed to potentially contaminated environments. The study will be carried out in two stages: i) Randomized Controlled Trial with reduced sample to confirm the sample size calculation (pilot trial), and ii) Randomized Controlled Trial (RCT). The RCT will be conducted with healthcare professionals who have contact with environments/patients infected by SARS-CoV-2 in hospital sectors with greater vulnerability to infection (urgency, emergency and intensive care units). The RCT will be conducted initially with a group of sixty participants (n = 30 in each group) for initial investigation of the potential for efficacy with the use of the respirators (VESTA and conventional N95) in two sectors (emergency and ICU) in a reference Hospital for COVID-19. The RCT will consist of two parallel groups: (1) Experimental Group (GExp) that will use the novel respirator (VESTA) and (2) Control Group (CG) that will use the standard respirator (N95). Participants will be recruited from participating hospitals and will be accompanied by 21 days in approximately eight consecutive shifts (ranging from shifts lasting 6 to 12 hours each, followed by approximately 36 hours of rest). Participants will be assessed at baseline (T0), at the end of the 10th day (T1), and at the end of the 21st day (T2).

NCT ID: NCT04489628 Withdrawn - SARS-CoV Infection Clinical Trials

Tele-health Enabled Clinical Trial for COVID-19

Start date: August 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the efficacy of high dose Vitamin D (an over-the-counter nutritional supplement) in preventing immune-related complications in outpatients with confirmed SARS-CoV-2 infection.